Given the association between CSPG4 expression in EVs of the mutated EGFR‐driven NSCLC cells in vitro and osimertinib refractoriness, we next evaluated CSPG4 levels on serum‐isolated EVs of the NSCLC patient cohort at baseline and progression (Table 1). Here, CSPG4 is linked to non-small cell lung carcinoma.